News|Articles|November 1, 2013

Dow Chemical and Cambrex Complete Facility for Drug-Solubility Solutions

Author(s)Pharmaceutical Technology Editors

Dow Chemical and Cambrex open a new facility for Dow?s hydroxypropyl methylcellulose acetate succinate (HPMCAS).

Dow Chemical and Cambrex have opened a new facility for Dow’s hydroxypropyl methylcellulose acetate succinate (HPMCAS) for drug solubility enhancement at Cambrex’s site in karlskoga, Sweden. The Cambrex Karlskoga expansion began in early 2013.

The facility completion and start of the HPMCAS product validation is part of the solubilization partnership between Dow and Bend Research, announced in October 2012. Beginning in 2014, Dow will be able to commercially supply solubility enabling excipients.

Source: Dow Chemical

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.